NEW YORK (GenomeWeb) – Biodesix today announced that its VeriStrat test has received a positive coverage decision from CareFirst Blue Cross Blue Shield.
VeriStrat is a blood-based proteomic test that helps guide treatment decisions for patients with non-small cell lung cancer.
CareFirst announced its position to extend coverage for the VeriStrat test in March and published a positive coverage policy earlier this week on its website, Biodesix said.
"This decision is great news for CareFirst BCBS' members who can now be confident of coverage when their physicians choose VeriStrat to help guide their treatment decisions," Biodesix CEO David Brunel said in a statement.
A study sponsored by the firm and published in March in the journal Lung Cancer found that the test decreased total lifetime direct cost by $135 per patient.
CareFirst covers 3.4 million patients in Maryland, the District of Columbia, and parts of Virginia.